POTENTIAL ROLE OF POTASSIUM AS A DETERMINANT OF MORBIDITY AND MORTALITY IN PATIENTS WITH SYSTEMIC HYPERTENSION AND CONGESTIVE HEART-FAILURE

被引:32
|
作者
PACKER, M
机构
来源
AMERICAN JOURNAL OF CARDIOLOGY | 1990年 / 65卷 / 10期
关键词
D O I
10.1016/0002-9149(90)90251-U
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Prehistoric animals and humans consumed a diet low in sodium but high in potassium, and thus, evolutionary forces fostered the development of physiologic systems that conserved sodium and excreted potassium. With the advent of civilized societies, food cooking and processing have greatly increased the sodium but decreased the potassium content of the diet. However, there has been little time for physiologic systems to adapt. The resulting excess of sodium has been implicated as an important factor in the development of hypertension and congestive heart failure. This traditional focus on sodium has ignored the potential role that an inadequate dietary intake of potassium might play in the degenerative diseases of the heart, brain and kidney. Yet dietary potassium may be as powerful a determinant of cardiovascular morbidity and mortality as dietary sodium. In experimental and clinical hypertension, an increased intake of potassium (without a change in dietary sodium) can reduce blood pressure, may suppress the activity of the sympathetic nervous and renin-angiotensin systems, and can prevent the development of vascular injury; conversely, potassium depletion has been associated with an increase in stroke and sudden death. In patients with chronic heart failure, potassium can modify both the mechanical and electrical properties of the heart, it can exert diuretic effects, and it can reduce the frequency and complexity of potentially lethal ventricular tachyarrhythmias. Given this central role, the effects of many pharmacologic interventions on the morbidity and mortality of patients with hypertension or chronic heart failure can be enhanced or diminished by the effect that these treatments might have on potassium homeostasis. Such inventions may include convertingenzyme inhibitors, β blockers, calcium channel blockers and positive inotropic agents. These observations indicate that the maintenance of potassium balance should be an important goal in the management of both cardiovascular disorders. © 1990.
引用
收藏
页码:E45 / E51
页数:7
相关论文
共 50 条
  • [1] THE EFFECT OF PROPRANOLOL ON MORTALITY AND MORBIDITY IN PATIENTS WITH CONGESTIVE HEART-FAILURE - THE BHAT EXPERIENCE
    GOLDSTEIN, S
    CHADDA, K
    BYINGTON, R
    CIRCULATION, 1984, 70 (04) : 6 - 6
  • [2] ROLE EFFECTIVENESS OF A PHARMACIST IN THE MAINTENANCE OF PATIENTS WITH HYPERTENSION AND CONGESTIVE HEART-FAILURE
    SCHNEIDER, PJ
    LARRIMER, JN
    VISCONTI, JA
    MILLER, WA
    CONTEMPORARY PHARMACY PRACTICE, 1982, 5 (02) : 74 - 79
  • [3] 6 CASES OF CONGESTIVE HEART-FAILURE ASSOCIATED WITH SYSTEMIC HYPERTENSION
    KAWAMURA, K
    HIROTA, Y
    SAITO, T
    KAKU, K
    SHIMIZU, G
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1983, 47 (03): : 374 - 374
  • [4] Morbidity and Mortality of Congestive Heart Failure in Trauma Patients
    Alkhawam, Hassan
    Madanieh, Raef
    El-hunjul, Mohammed
    Madanieh, Abed
    Syed, Umer
    Ahmad, Sumair
    Lieber, Joseph J.
    Vittorio, Timothy J.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2016, 352 (02): : 172 - 176
  • [5] MORBIDITY AND MORTALITY OF CONGESTIVE HEART FAILURE IN TRAUMA PATIENTS
    Madanieh, Raef
    Alkhawam, Hassan
    El-hunjul, Mohammed
    Madanieh, Abed
    Bakhsh, M. Umair
    Vittorio, Timothy
    CLINICAL CARDIOLOGY, 2015, 38 : 7 - 8
  • [6] ARRHYTHMIAS AND MORTALITY IN CONGESTIVE HEART-FAILURE
    KJEKSHUS, J
    AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (19): : I42 - I48
  • [7] SODIUM AND POTASSIUM CONCENTRATIONS IN ERYTHROCYTES OF PATIENTS WITH CONGESTIVE HEART-FAILURE
    OKUMURA, K
    OGAWA, K
    MIZUTANI, K
    KATO, T
    JAPANESE HEART JOURNAL, 1988, 29 (02): : 135 - 142
  • [8] EFFECTS OF VESNARINONE ON MORBIDITY AND MORTALITY IN PATIENTS WITH HEART-FAILURE
    FELDMAN, AM
    BRISTOW, MR
    PARMLEY, WW
    CARSON, PE
    PEPINE, CJ
    GILBERT, EM
    STROBECK, JE
    HENDRIX, GH
    POWERS, ER
    BAIN, RP
    WHITE, BG
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03): : 149 - 155
  • [9] PHARMACOKINETICS AND PHARMACODYNAMICS OF ENALAPRIL IN PATIENTS WITH CONGESTIVE HEART-FAILURE AND PATIENTS WITH HYPERTENSION
    SCHWARTZ, JB
    TAYLOR, A
    ABERNETHY, D
    OMEARA, M
    FARMER, J
    YOUNG, J
    NELSON, E
    POOL, J
    MITCHELL, JR
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1985, 7 (04) : 767 - 776
  • [10] ROLE OF NITRATES IN CONGESTIVE HEART-FAILURE
    COHN, JN
    AMERICAN JOURNAL OF CARDIOLOGY, 1987, 60 (15): : H39 - H43